Stifel analyst Stephen Willey noted that Proteon Therapeutics management said they intend to evaluate strategic options following the failure of the PATENCY-2 trial of vonapanitase in patients with chronic kidney disease, but he believes the options appear limited and sees a cash distribution to shareholders as a likely outcome. He estimates a residual fair value of approximately 40c per share.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.